9 November 2020 - Advice on eight new medicines for use in conditions including breast cancer, lung cancer and osteoporosis has today been published by the Scottish Medicines Consortium.

An initial assessment report has been published for volanesorsen (Waylivra), which can be used to treat familial chylomicronaemia syndrome.

Atezolizumab (Tecentriq) was accepted for the treatment of metastatic triple negative breast cancer following consideration through SMC’s Patient and Clinician Engagement process, which is used for medicines to treat end of life and rare conditions.

Read SMC press release